These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 30690502)
1. Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder. Shi Z; Jagannathan K; Wang AL; Fairchild VP; Lynch KG; Suh JJ; Childress AR; Langleben DD Int J Neuropsychopharmacol; 2019 Mar; 22(3):180-185. PubMed ID: 30690502 [TBL] [Abstract][Full Text] [Related]
2. Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment. Nunes EV; Scodes JM; Pavlicova M; Lee JD; Novo P; Campbell ANC; Rotrosen J Am J Psychiatry; 2021 Jul; 178(7):660-671. PubMed ID: 34170188 [TBL] [Abstract][Full Text] [Related]
3. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985 [TBL] [Abstract][Full Text] [Related]
4. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial. DeFulio A; Everly JJ; Leoutsakos JM; Umbricht A; Fingerhood M; Bigelow GE; Silverman K Drug Alcohol Depend; 2012 Jan; 120(1-3):48-54. PubMed ID: 21782353 [TBL] [Abstract][Full Text] [Related]
5. Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder. Shi Z; Wang AL; Jagannathan K; Fairchild VP; O'Brien CP; Childress AR; Langleben DD J Psychiatry Neurosci; 2018 Jul; 43(4):254-261. PubMed ID: 29947607 [TBL] [Abstract][Full Text] [Related]
6. A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder. Sullivan MA; Bisaga A; Pavlicova M; Carpenter KM; Choi CJ; Mishlen K; Levin FR; Mariani JJ; Nunes EV Am J Psychiatry; 2019 Feb; 176(2):129-137. PubMed ID: 30336703 [TBL] [Abstract][Full Text] [Related]
7. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison. Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855 [TBL] [Abstract][Full Text] [Related]
8. Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment. Gordon MS; Vocci FJ; Fitzgerald TT; O'Grady KE; O'Brien CP Contemp Clin Trials; 2017 Feb; 53():130-136. PubMed ID: 28011389 [TBL] [Abstract][Full Text] [Related]
9. [An interim analysis of the results of treatment program implementation with the use of injectable extended-release naltrexone for opioid addicted patients]. Agibalova TV; Nedobylskiy OV; Poplevchenkov KN; Sirotko II; Shcherban AV; Tsarev SA Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):32-34. PubMed ID: 28745668 [TBL] [Abstract][Full Text] [Related]
10. Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial. Everly JJ; DeFulio A; Koffarnus MN; Leoutsakos JM; Donlin WD; Aklin WM; Umbricht A; Fingerhood M; Bigelow GE; Silverman K Addiction; 2011 Jul; 106(7):1309-18. PubMed ID: 21320227 [TBL] [Abstract][Full Text] [Related]